17,261 trials
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Muscular Dystrophies · Muscular Dystrophy, Duchenne · Muscular Disorders, Atrophic
Primary: Change From Baseline in Functional Capacity as Assessed by the Mid-level (Elbow) Dimension Score of the Performance of Upper Limb (PUL) Version 1.2 at Month 12 — 65.5…
Dermatitis, Seborrheic · Dry Skin; Eczema
Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001
Pulmonary Fibrosis
Primary: Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants — -2.807; -3.068; -1.120 Percent change from baseline in ppFVC
Coronary Heart Disease (CHD)
Primary: Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA)…
Advanced Haematological Malignancies
Primary: Module 1: Number of Participants With Adverse Events — 9; 28; 4; 16 Participants
Antibiotic-associated Diarrhea
Primary: Number of Participants Experiencing Diarrhea — 3; 2; 122; 128 Participants
Alcohol Use Disorder · Couples
Primary: Change in Percent Days Abstinent - Measured by Time Line Follow Back (TLFB) — 36.8; 35.9 percentage of days abstinent for alcohol
Metastatic Melanoma
Primary: Number of Participants With Adverse Events — 30; 10; 4 Participants
Anxiety
Primary: Change in Recognition Ratings (Positive Interpretation Bias) — 1.23; 1.19; 1.22; 1.16 score on a scale — p=0.005
Vitiligo
Primary: Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48 — 6.58; 6.87; -3.43; -3.46 scores on a scale
Covid19
Primary: Safety of CAP-1002: Incidence of All-Cause Mortality — 5; 6 Participants
Influenza, Human
Primary: Hemagglutination-inhibiting (HI) Antibody Titers Against Vaccine-homologous H5N8 — 117.5; 175.2; 121.8; 176.6 Titer
Influenza · Healthy Volunteers
Primary: Geometric Mean of Hemagglutination Inhibition (HAI) Antibody (Ab) Titer at Day 22 — 5.74; 5.61; 5.28 titer
Neoplasms by Site
Primary: Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E — 54.8; 56.6; 81.4; 63.9 ug/mL